Personalis
Personalis Reports Preliminary Q4 Revenues up More Than 2 Percent
The company is expecting continued growth in its oncology orders in Q4 2021 to translate to significant revenue growth for that business next year.
Fulgent Genetics, Bio-Techne Lead Winners as GenomeWeb Index Gains 12 Percent in 2021
While Fulgent's stock price nearly doubled, at the other end of the spectrum, Berkeley Lights saw an 80 percent decline in its share price.
Personalis Signs Deal With BTIG for $100M At-Market Stock Offering
The company said any proceeds raised will support working capital and general corporate purposes, including research and development programs.
Personalis Q3 Revenues Climb 12 Percent
The company saw less revenue from the VA MVP during the quarter but reported a surge in both revenue and new orders from non-VA pharma and other customers.
Aug 4, 2021
Personalis Q2 Revenues Rise 11 Percent
May 5, 2021
Personalis Q1 Revenues Grow 9 Percent
Feb 26, 2021
Feb 25, 2021
Personalis Q4 Revenues up 11 Percent
Jan 27, 2021
Personalis Prices $150M Public Stock Offering
Jan 12, 2021
Personalis Projects 2020 Q4 Revenues Up 11 Percent
Dec 23, 2020
Nov 5, 2020
Personalis Q3 Revenues Up 16 Percent
Aug 12, 2020
Personalis Prices $125M Public Stock Offering
Aug 6, 2020